Aptamer Group plc has unveiled a cutting-edge biomarker discovery service aimed at empowering researchers in the pharmaceutical, biotechnology, and diagnostic sectors with a fresh approach to identifying and validating new disease markers. By leveraging their proprietary Optimer technology and advanced proteomic analysis, Aptamer Group offers an unbiased and high-throughput method for biomarker identification. This innovative platform stands out by not only identifying biomarkers but also generating corresponding affinity ligands, known as aptamers, simultaneously.
The Optimer technology, consisting of short, synthetic oligonucleotide molecules with enhanced stability and binding specificity, plays a crucial role in distinguishing between healthy and diseased cell or tissue samples. Following this initial step, precise identification of molecular biomarkers is achieved through proteomic analysis. This unique approach results in the delivery of validated biomarkers and immediately applicable aptamers, or opens up avenues for pursuing the identified biomarkers with alternative modalities like antibodies.
Unlike traditional biomarker discovery methods that often entail prolonged screening and validation processes, Aptamer’s integrated approach helps expedite these timelines for researchers. Furthermore, this service can aid drug developers in identifying biomarkers that align with specific strategies, such as receptor-mediated endocytosis for drug delivery purposes, thereby enhancing the translation of identified biomarkers and reducing development timelines.
A notable demonstration of the platform’s capabilities was exhibited through the internal identification of biomarkers for fibrotic liver targeting by the company. This successful validation underscores the platform’s potential in pinpointing novel targets with immediate therapeutic or diagnostic significance, showcasing its applicability in real-world scenarios.
Key Takeaways:
– Aptamer Group’s biomarker discovery service integrates Optimer technology and proteomic analysis for efficient identification and validation of disease markers.
– The platform’s innovative approach accelerates biomarker discovery timelines and supports drug delivery strategies.
– Aptamer’s service offers a fee-for-service model, enabling research teams to access advanced biomarker discovery capabilities without internal infrastructure investments.
– The integrated approach has garnered interest from pharmaceutical and biotechnology partners, highlighting its value in streamlining biomarker discovery processes.
Tags: drug delivery
Read more on news-medical.net